0102030405
Apalutamide CAS No 956104-40-8 Pharmaceutical Raw Material
02
introduce
introduce
Apalutamide (ARN-509) is a potent, selective second-generation androgen receptor inhibitor and key antineoplastic pharmaceutical API. It specifically targets the androgen receptor to block prostate cancer cell growth and spread, with proven clinical efficacy in treating castration-resistant and castration-sensitive prostate cancer.
Our products adhere to strict international quality standards, ensuring high purity, stable performance, and reliable supply for pharmaceutical formulation and biomedical research.
02
Physical and chemical properties
Apalutamide exhibits critical physicochemical characteristics supporting its pharmaceutical and research applications, as follows:
- Form: Odorless solid
- Density: 1.59±0.1 g/cm³
- pKa: 13.83±0.46
- Solubility: Soluble in DMSO (≥ 23.85 mg/mL) and Ethanol (≥ 7.33 mg/mL), insoluble in water
- Form: Odorless solid
- Density: 1.59±0.1 g/cm³
- pKa: 13.83±0.46
- Solubility: Soluble in DMSO (≥ 23.85 mg/mL) and Ethanol (≥ 7.33 mg/mL), insoluble in water
1. High Selectivity: Specifically antagonizes the androgen receptor without significant cross-reactivity with other receptors, minimizing off-target effects.
2. Clear Mechanism of Action: Blocks androgen receptor nuclear translocation, DNA binding, and transcriptional activation, directly inhibiting prostate cancer cell proliferation.
3. Broad Clinical Indications: FDA-approved for both non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), addressing unmet clinical needs.
4. Favorable Pharmacokinetics: High oral bioavailability and long plasma half-life enable convenient once-daily administration, improving patient compliance.
5. Proven Efficacy: Induces durable tumor regression and PSA declines in preclinical models and clinical trials, enhancing patient prognosis.
2. Clear Mechanism of Action: Blocks androgen receptor nuclear translocation, DNA binding, and transcriptional activation, directly inhibiting prostate cancer cell proliferation.
3. Broad Clinical Indications: FDA-approved for both non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), addressing unmet clinical needs.
4. Favorable Pharmacokinetics: High oral bioavailability and long plasma half-life enable convenient once-daily administration, improving patient compliance.
5. Proven Efficacy: Induces durable tumor regression and PSA declines in preclinical models and clinical trials, enhancing patient prognosis.
Primarily indicated for the treatment of prostate cancer, with specific applicable scenarios including:
1. Non-metastatic castration-resistant prostate cancer (NM-CRPC): Suitable for patients whose disease progresses after hormonal therapy but cancer cells have not spread, serving as the core therapeutic drug for this indication.
2. Metastatic castration-sensitive prostate cancer (mCSPC): Approved for the treatment of such patients, providing a new treatment option for metastatic prostate cancer.
3. Metastatic castration-resistant prostate cancer (CRPC): Can be used for metastatic patients whose disease progresses after prior treatment, effectively inhibiting tumor growth and relieving symptoms.
1. Non-metastatic castration-resistant prostate cancer (NM-CRPC): Suitable for patients whose disease progresses after hormonal therapy but cancer cells have not spread, serving as the core therapeutic drug for this indication.
2. Metastatic castration-sensitive prostate cancer (mCSPC): Approved for the treatment of such patients, providing a new treatment option for metastatic prostate cancer.
3. Metastatic castration-resistant prostate cancer (CRPC): Can be used for metastatic patients whose disease progresses after prior treatment, effectively inhibiting tumor growth and relieving symptoms.
We implement strict full-process quality control, with each batch of Apalutamide undergoing rigorous testing of key indicators including purity, solubility, stability, and biological activity to meet GMP, USP, EP, and BP standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to meet customer-specific needs.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to meet customer-specific needs.
As a leading second-generation androgen receptor inhibitor, Apalutamide plays an irreplaceable role in targeted prostate cancer therapy, transforming treatment outcomes for patients worldwide. With its high selectivity, proven clinical efficacy, exceptional product quality, and reliable supply capacity, we are committed to providing high-quality Apalutamide API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Apalutamide to meet your needs in pharmaceutical formulation, oncology research, and clinical treatment. Contact us for more product details and cooperation support.
Choose our Apalutamide to meet your needs in pharmaceutical formulation, oncology research, and clinical treatment. Contact us for more product details and cooperation support.